Fig. 1.
![Fig. 1. Annual hazard rates of end-stage liver disease (ESLD) and nonhepatic deaths among hepatitis C virus (HCV)–seropositive participants in the MHCS. / By HIV status (positive [HIV+] or negative [HIV−]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/100/5/10.1182_blood.v100.5.1584.h81702001584_1584_1589/3/h81723060001.jpeg?Expires=1723926545&Signature=g2s1w0gE9LF5~c2tsPfR7~CAtc9k0Jv0Oq8tuVwH03p6lhvCng0juo6ztYjFqrP5pu77EFBJsEZEHufY5e7CHB6lkDTaUJXi5IWnFDE1kluvH-HNzrKD1gIA7TRjBFt9Zx4QWx9Qp986udr-2bIQtIN7poDQhiJW7BKu0REfhzverNX4DacbpUPrmHGckiT27hyINsafEoh0nDE0le6FHS-CbP8CeJXLCm~1d7XvI4YGvY9CiAlH564~pgAe2vSEWP0ujvnXX4yDKSCMrym3WvUIRgVXM7jfhaLgntwAqKhUMmik5IsTuP53Frx4SvinLwbzC4reu~3rp1WOWEDNJw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Annual hazard rates of end-stage liver disease (ESLD) and nonhepatic deaths among hepatitis C virus (HCV)–seropositive participants in the MHCS.
By HIV status (positive [HIV+] or negative [HIV−]).
Annual hazard rates of end-stage liver disease (ESLD) and nonhepatic deaths among hepatitis C virus (HCV)–seropositive participants in the MHCS.
By HIV status (positive [HIV+] or negative [HIV−]).
